PineTree Therapeutics is a pre-clinical stage Biotech company headquartered in Cambridge, MA and was founded in 2019. It has developed the TAER-TAB™ and ViTRAP™ technologies and is building a broad pipeline for hard-to-treat cancers and viral diseases, with an initial focus on oncology. TAER-TAB™, Tumor Associated Essential Receptor Targeting AntiBody, is a transformative antibody based receptor degradation platform that targets and potentially degrades drug-resistant or difficult-to-treat receptors present on many types of tumors and on different types of immune and disease cells. It has potential to generate many multivalent antibodies to degrade extracellular oncogenic receptors of interest as well as immuno-oncology antibodies to enhance adoptive anti-tumor immunity and prevent tumor recurrence.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $17M
Founded date: 2019
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.08.2024 | Series A | $17M | - |
Mentions in press and media 6
| Date | Title | Description |
| 11.08.2024 | Pinetree Therapeutics: $17 Million (Series A) Raised To Advance Protein Degradation Platform | Pinetree Therapeutics, a biotechnology company developing next-generation targeted protein degraders (TPD) to combat drug resistance in oncology and beyond, announced the completion of a Series A funding round, raising $17 million from new ... |
| 30.07.2024 | Pinetree Therapeutics Raises $17M in Series A Funding | Pinetree Therapeutics, Inc., a Cambridge, MA-based biotechnology company advancing next-generation targeted protein degraders (TPD) to combat drug resistance in oncology and beyond, raised $17m in Series A funding round. The round was co-le... |
| 30.07.2024 | Pinetree Therapeutics Closes $17 Million in Series A Funding to Advance AbReptor™ Protein Degradation Platform and Portfolio Programs | New investment supports continued development of multispecific antibody degraders for oncology and other therapeutic areas CAMBRIDGE, Mass., July 30, 2024 /PRNewswire/ -- Pinetree Therapeutics, Inc. ("Pinetree" or the "Compan... |
| 23.07.2024 | Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate with AstraZeneca | Pinetree to receive up to $45 million in upfront and near-term payments, with a total deal value of over $500 million including potential additional development and commercial milestone payments CAMBRIDGE, Mass., July 23, 2024 /PRNewswire/ ... |
| 08.06.2022 | PineTree Therapeutics Raises $23.5M in Series A1 Funding | PineTree Therapeutics, a Cambridge, MA-based biotech company which specializes in therapies in oncology, immuno-oncology and other diseases, raised $23.5M in Series A1 funding. Backers included InterVest, SK Securities, DSC Investment, J Cu... |
| - | PineTree Therapeutics | - |